VAPO - Vapotherm, Inc.

NYSE - NYSE Delayed Price. Currency in USD
16.94
-0.20 (-1.17%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close17.14
Open17.11
Bid16.58 x 800
Ask16.90 x 1100
Day's Range16.56 - 17.29
52 Week Range14.70 - 22.29
Volume19,191
Avg. Volume37,640
Market Cap293.846M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-14.65
Earnings DateMay 7, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.33
Trade prices are not sourced from all markets
  • Business Wire8 days ago

    Vapotherm to Report First Quarter 2019 Financial Results

    Vapotherm, Inc. (VAPO) (“Vapotherm”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced today that it will release financial results for the first quarter of 2019 after the close of trading on Tuesday, May 7, 2019. Vapotherm’s management team will host a corresponding conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to a live webcast, please visit the Investors section of the Vapotherm’s website at: http://investors.vapotherm.com/events-and-presentations/events.

  • Business Wirelast month

    Emergency Department Subgroup Study Showed Hi-VNI® Technology Had Similar Outcomes to Non-invasive Positive Pressure Ventilation in Management of Respiratory Distress Among Acute Decompensated Heart Failure Patients

    Vapotherm, Inc. (VAPO), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology, today announced that a paper published in the American Journal of Emergency Medicine, titled “HVNI vs NIPPV in the treatment of Acute Decompensated Heart Failure: subgroup analysis of a multi-center trial in the ED” showed equivalent outcomes between Hi-VNI Technology and Non-invasive Positive Pressure Ventilation (NiPPV) in the treatment of respiratory distress in a subgroup of patients suffering from acute decompensated heart failure (ADHF). “These results represent another proof point that Vapotherm Hi-VNI Technology is a viable alternative to relieve undifferentiated respiratory distress across a wide variety of patient populations,” said Joe Army, President and CEO.

  • GuruFocus.comlast month

    Vapotherm Inc (VAPO) Files 10-K for the Fiscal Year Ended on December 31, 2018

    For the last quarter Vapotherm Inc reported a revenue of $42.4 million, compared with the revenue of $30.12 million during the same period a year ago. Warning! GuruFocus has detected 1 Warning Sign with VAPO.

  • Associated Presslast month

    Vapotherm: 4Q Earnings Snapshot

    The Exeter, New Hampshire-based company said it had a loss of $1.39 per share. Losses, adjusted to extinguish debt, came to $1.28 per share. The medical technology company posted revenue of $11.7 million ...

  • Business Wirelast month

    Vapotherm Reports Fourth Quarter and Fiscal Year 2018 Financial Results

    2018 Revenue of $42.4 Million Reflects 19.0% Increase Over Prior Year

  • ACCESSWIRElast month

    Vapotherm, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 12, 2019 / Vapotherm, Inc. (NYSE: VAPO ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 12, 2019, 2018 at 4:30 PM ...

  • Business Wire2 months ago

    Vapotherm® Releases Next Generation of Capital Unit: Precision Flow Hi-VNI™ System

    Vapotherm, Inc. (VAPO), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced the release of the next generation of its capital unit: the Precision Flow Hi-VNI system. For this generation of the Precision Flow® system, both the hardware and software have been updated to improve reliability, and to comply with the EMC 4th Edition requirements for medical devices, IEC 60601-1-2:2014. As with all the other models of the Precision Flow system, this generation provides Hi-VNI Technology, the innovation that delivers Mask-Free NIV™ for spontaneously breathing patients.

  • Business Wire4 months ago

    Vapotherm to be Added to the Russell 2000®, 3000® and Microcap® Indexes

    Vapotherm, Inc. (VAPO) announced today that it has been added to the Russell 2000®, Russell 3000® and Russell Microcap® Indexes, effective after market close on December 21, 2018, as part of Russell’s quarterly addition of companies with recent initial public offerings. The Russell 2000 Index measures the performance of the small-cap segment of the U.S. equity market and is a subset of the Russell 3000 Index. Membership in the Russell 2000 Index includes automatic inclusion in the appropriate growth and style indexes, such as the Russell Microcap Index, which represents small-cap and micro-cap stocks.

  • Business Wire5 months ago

    Clinical Study Shows Vapotherm’s New IntellO2™ Module for Precision Flow® System Significantly Improves Maintenance of Premature Neonates in Target Oxygenation Range

    Vapotherm, Inc. today announced the publication of a key prospective, multi-center, controlled, order-randomized crossover trial. The study demonstrates that using the IntellO2 automated oxygen controller module helped clinicians maintain neonates in the physician-prescribed oxygen saturation range significantly better than manual control alone. The results were published by Reynolds and colleagues in the Archives of Disease in Childhood: Fetal and Neonatal Edition, entitled “Randomised crossover study of automated oxygen control for preterm infants receiving nasal High Flow.” The data show that trained staff were able to keep the babies’ oxygen saturation in the target range 49% of the time with manual controls alone.

  • Business Wire5 months ago

    Vapotherm Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    Vapotherm, Inc. (VAPO) (“Vapotherm”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced the closing of its initial public offering of 4,600,000 shares of common stock, at a price to the public of $14.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 600,000 shares of common stock. All of the shares of common stock were offered by Vapotherm.

  • Business Wire5 months ago

    Vapotherm Announces Pricing of Initial Public Offering

    Vapotherm, Inc. , a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced the pricing of its initial public offering of 4,000,000 shares of common stock at a price to the public of $14.00 per share.